Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer

201540 citationsJournal Articlehybrid Open Access

Authors

for the CERVIFARM-300-II Study Group

M R Sarduy · Higher Institute of Technologies and Applied Sciences

Imalvet Santiesteban García · Centro de Ingeniería Genética y Biotecnología

Marco A. Coca · Ministerio de Salud Pública

Abel Hernández Perera · Ministerio de Salud Pública

Loida Torres · Ministerio de Salud Pública

Carmen Valenzuela · Centro de Ingeniería Genética y Biotecnología

Abstract

Intralesional injections of 70 mg CIGB-300 in two sites (0.5 ml per injection) and this treatment plan are recommended to be evaluated in phase 2 studies.

Topics & Keywords

Peptidase Inhibition and Analysis Cell Adhesion Molecules Research Immunotherapy and Immune Responses

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Cancer

Volume 112, Issue 10, pp. 1636-1643

DOI: 10.1038/bjc.2015.137

Field-Weighted Citation Impact: 1.72